Figure 9. Hypothetical model of the anti‐influenza activity of succinate.

Succinate triggers a unique succinylation modification of K87 in the NP of IAV which further alters the electrostatic environment of the vRNA binding site. As a result, the formation of vRNPs particles is impaired. This further contributes to an inhibition of viral multiplication as well as viral‐induced inflammatory response. In vivo, IAV‐infected mice treated intranasally with succinate are more resistant to the development of acute pneumonia.